Synthetic Gene Circuits & Their Relevance To The Challenges Of Genome Editing
In this Audio Q&A we discuss genome modification and synthetic gene circuits. Topics include the engineering of synthetic gene circuits and the role they play in controlling gene expression and protein levels in cell.
Gabor will be joining us again at Oxford Global's NextGen Omics US: In-Person, as part of a 5th Annual Genome Editing Congress. He will be presenting in March on genome editing for mapping metastatic fitness landscapes. If you would like to join you can view the event page here.
Speaker Biographies
GĂĄbor BalĂĄzsi - Henry Laufer Professor, Stony Brook University
GĂĄbor BalĂĄzsi received his undergraduate Physics degree at the BabeĹ-Bolyai University in KolozsvĂĄr (Cluj), Romania. In 1997, he started graduate school at the University of Missouri at Saint Louis, USA, as a PhD student with Professor Frank Moss. His PhD research was on perturbation propagation and synchronization in normal and epileptic neurons and glial cells. In 2002, he continued as a postdoctoral fellow in Systems Biology at Northwestern University in Chicago, studying gene-regulatory network response to environmental changes with Professors ZoltĂĄn N. Oltvai and Albert-LĂĄszlĂł BarabĂĄsi. In 2005 he became a postdoctoral fellow at Boston University with Professor James J. Collins. There he designed synthetic gene circuits to study how cellular diversity promotes drug resistance. He continued and expanded these efforts in his own laboratory over the last decade (8 of which were at the University of Texas MD Anderson Cancer Center in Houston, Texas), building a growing library of synthetic gene circuits first in yeast, and then in cancer cells. As the Henry Laufer Associate Professor of Physical and Quantitative Biology at Stony Brook University he leads an interdisciplinary research group, which utilizes synthetic gene circuits to control gene expression in yeast and human cells. Their goal is to understand fundamental biological processes underlying microbial drug resistance and cancer. Dr. BalĂĄzsi was one of the recipients of the 2009 NIH Directorâs New Innovator Award, which was created to âstimulate highly innovative research and support promising new investigatorsâ. His research group is half-experimental and half-computational, fostering interdisciplinary training while advancing the frontiers of quantitative biology.